This is a quick summary of the main discovery for each research paper we have published, organized issue by issue. Each key finding is below the article title, with a link to the abstract.
The effects of cannabis intoxication on motor vehicle collision revisited and revised
Acute cannabis intoxication is associated with a small but statistically significant increase in motor vehicle crash risk.
Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized controlled trials
Current evidence does not support the use of topiramate to improve treatment retention for cocaine use disorder.
Gender-specific effects of comorbid depression and anxiety on the propensity to drink in negative emotional states
Female alcoholics seem to have a higher prevalence than males of comorbid depression and anxiety disorders and tendency to drink in negative emotional situations.
Daily alcohol use as an independent risk factor for HIV seroconversion among people who inject drugs
Daily alcohol use appears to be an independent risk factor for HIV seroconversion among people who inject drugs.
A randomized trial of a pain management intervention for adults receiving substance use disorder treatment
Among adults with pain receiving addictions treatment, a psychological pain management intervention appears to reduce pain and alcohol use and improve pain-related functioning over 12 months.
Estimating demand for primary care-based treatment for substance and alcohol use disorders
In the US, people with substance or alcohol use disorders seem more willing to enter treatment in a primary care setting than in a specialty drug treatment centre.
Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study
Buprenorphine + naloxone, used in combination with naltrexone, may be associated with reductions in cocaine use among people with cocaine dependence.
A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults
Longer (56-day) buprenorphine taper produces better opioid abstinence and retention outcomes than shorter (28-day) taper for opioid-dependent youth.
Effectiveness of a universal internet-based prevention program for ecstasy and new psychoactive substances: a cluster randomized controlled trial
A universal online school-based prevention program appeared to reduce students' intentions to use new psychoactive substances (NPS) and increased knowledge about ecstasy and NPS in the short term.
Depression motivates quit attempts but predicts relapse: differential findings for gender from the International Tobacco Control Study
Smokers with depressive symptoms or diagnosis make more quit attempts than their non-depressed counterparts but are likelier to relapse in the first month.
Problem gambling and the five-factor model of personality: a large population-based study
Higher severity problem gambling may be associated with higher neuroticism scores and lower conscientiousness and agreeableness scores in the Mini-International Personality Item Pool.
Adolescent smoking and tertiary education: opposing pathways linking socio-economic background to alcohol consumption
In Britain, young adults are more likely to drink heavily both if they smoke and if they participate in tertiary education (college and university).
The impact of quitting smoking on depressive symptoms: findings from the International Tobacco Control Four-Country Survey
Most people who stop smoking appear to be at no greater risk of developing symptoms of depression than if they had continued smoking.
Ecological momentary assessment of working memory under conditions of simultaneous marijuana and tobacco use
The putative effect of marijuana on working memory and the facilitative effect of tobacco on working memory are no longer present when used simultaneously with tobacco and alcohol, respectively.
Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers
Nalmefene, a drug used to treat alcohol problems, was licensed for use in the UK despite insufficient evidence to prove its effectiveness.